Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T21:57:37.183Z.
Calculation as of: 2026-10-06T21:57:37.183Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$143.84M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.60M
PS Ratio
N/A
TTM Avg
79.91
3Y Avg
79.91
5Y Avg
79.91
Market Cap
$146.62M
PS Ratio
N/A
TTM Avg
636.97
3Y Avg
636.97
5Y Avg
636.97
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $143.84M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | N/A | 79.91 | 79.91 | 79.91 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | 5.46 | 16.79 | 41.83 | 132.05 |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 2.14 | 7.67 | 3.96 | 3.05 |
| Codexis, Inc. (CDXS)vs › | $146.28M | 1.88 | 2.61 | 3.23 | 4.75 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | 636.97 | 636.97 | 636.97 |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | 3.06 | 2.75 | 2.29 | 3.79 |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | 9.14 | 14.60 | 22.81 | 22.81 |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | 4.31 | 6.36 | 3.87 | 4.58 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from CAD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
